Phenibut vs Trazodone
Moderate Research vs FDA Approved
monitor Researched · 90% Both trazodone and phenibut have sedative properties. Combining them can result in excessive CNS depression, including profound drowsiness, impaired coordination, and respiratory depression at high doses. If used together, start with lower doses of both and avoid combining with alcohol or other CNS depressants.
Molecular Data
Phenibut Trazodone
Weight 179.22 Da 371.86 Da
Half-life ~5 hours ~5-9 hours
Type Phenyl-substituted GABA analog (C10H13NO2) Triazolopyridine derivative (C19H22ClN5O)
Key Benefits
Phenibut
01 Reduction of anxiety and social inhibition
02 Improved sleep onset and sleep quality
03 Mild mood elevation and sense of well-being
04 Reduced cognitive effects of stress without heavy sedation at low doses
05 Potential benefit for vestibular disorders (clinical use in Russia)
Trazodone
01 Effective sleep aid that improves sleep onset and sleep maintenance without the dependence risk of benzodiazepines
02 Enhances slow-wave (deep) sleep, which is critical for physical recovery and growth hormone release
03 Non-habit-forming with no significant tolerance development, even with long-term use
04 Widely used and well-tolerated solution for trenbolone-induced and steroid-related insomnia
05 Does not suppress REM sleep the way many other sleep medications do
06 Inexpensive, widely available as a generic, and has decades of safety data
Side Effects
Phenibut
Drowsiness and sedation, especially at higher doses
Dizziness and lightheadedness
Nausea and gastrointestinal discomfort (particularly with HCl form on empty stomach)
Tolerance develops rapidly, often within 2-3 days of consecutive use
Next-day grogginess or hangover-like effects
Headache
Trazodone
Morning drowsiness or grogginess (dose-dependent, more common above 50 mg)
Dry mouth
Dizziness or lightheadedness, particularly upon standing (orthostatic hypotension)
Headache
Nausea (reduced by taking with food)
Blurred vision
Contraindications
History of substance abuse or addiction (phenibut has high abuse potential)
Concurrent use of alcohol, benzodiazepines, GHB, barbiturates, or other CNS depressants
Renal impairment (phenibut is primarily excreted by the kidneys)
Pregnancy and breastfeeding (insufficient safety data)
History of seizure disorders (withdrawal may lower seizure threshold)
Current dependence on any GABAergic substance
Known hypersensitivity to trazodone
Concurrent use of MAOIs or use within 14 days of MAOI discontinuation
History of priapism or conditions predisposing to priapism (e.g., sickle cell disease, multiple myeloma, leukemia)
Severe hepatic impairment (dose adjustment required in moderate impairment)
Recent myocardial infarction or unstable cardiac conditions
Pregnancy, particularly first trimester (Category C; limited human data)
Research Evidence
Phenibut Trazodone
Status Moderate Research FDA Approved
References 5 studies 4 studies
Latest 2020 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.